Información de ANI Pharmaceuticals Inc, dividendo de ANI Pharmaceuticals Inc, actividades de los accionistas y más

Más Datos de ANI Pharmaceuticals Inc Compañía

ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.

Información de ANI Pharmaceuticals Inc



Símbolo de cotizaciónANIP

Nombre de la empresaANI Pharmaceuticals Inc

Fecha de salida a bolsaMay 04, 2000

Director ejecutivoLalwani (Nikhil Suresh)

Número de empleados897

Tipo de seguridadOrdinary Share

Fin del año fiscalMay 04

Dirección210 Main Street West

CiudadBAUDETTE

Bolsa de valoresNASDAQ OMX - NASDAQ BASIC

PaísUnited States of America

Código postal56623

Teléfono12186343500

Sitio Webhttps://www.anipharmaceuticals.com/

Símbolo de cotizaciónANIP

Fecha de salida a bolsaMay 04, 2000

Director ejecutivoLalwani (Nikhil Suresh)

Ejecutivos de ANI Pharmaceuticals Inc



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Chad Gassert

Senior Vice President - Corporate Development and Strategy

311.43K

+0.42%

Mr. Nikhil Suresh Lalwani

President, Chief Executive Officer, Director

290.27K

-45.36%

Mr. Muthusamy Shanmugam

Director, Head of Research and Development, Chief Operating Officer - Novitium Operations

82.54K

-22.14%

Mr. Ori Gutwerg

Senior Vice President - Generics

61.18K

-41.94%

Mr. Patrick D. Walsh

Independent Chairman of the Board

52.41K

-11.45%

Ms. Krista Davis

Chief Human Resources Officer, Senior Vice President

51.95K

-12.65%

Mr. Thomas Andrew (Thom) Rowland

Senior Vice President, Head of Established Brands

37.85K

-12.61%

Mr. Thomas J. (Tom) Haughey, J.D.

Independent Director

36.52K

--

Dr. Renee P. Tannenbaum, Pharm.D.

Independent Director

25.16K

--

Mr. Matthew J. (Matt) Leonard

Independent Director

6.86K

--

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Chad Gassert

Senior Vice President - Corporate Development and Strategy

311.43K

+0.42%

Mr. Nikhil Suresh Lalwani

President, Chief Executive Officer, Director

290.27K

-45.36%

Mr. Muthusamy Shanmugam

Director, Head of Research and Development, Chief Operating Officer - Novitium Operations

82.54K

-22.14%

Mr. Ori Gutwerg

Senior Vice President - Generics

61.18K

-41.94%

Mr. Patrick D. Walsh

Independent Chairman of the Board

52.41K

-11.45%

Ms. Krista Davis

Chief Human Resources Officer, Senior Vice President

51.95K

-12.65%

Desglose de ingresos

Divisa: USDActualizado: lun., 6 de abr

FY2025

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

Por negocioUSD

Nombre

Ganancia

Proporción

Sales of generic pharmaceutical products

384.11M

43.48%

Sales of rare disease pharmaceutical products

347.78M

39.37%

Sales of Cortrophin Gel

347.78M

39.37%

Sales of branded pharmaceutical products

76.61M

8.67%

Por regiónUSD

Nombre

Ganancia

Proporción

United States

852.44M

96.50%

International

30.92M

3.50%

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

Sales of generic pharmaceutical products

384.11M

43.48%

Sales of rare disease pharmaceutical products

347.78M

39.37%

Sales of Cortrophin Gel

347.78M

39.37%

Sales of branded pharmaceutical products

76.61M

8.67%

Estadísticas de accionistas

Actualizado: dom., 10 de may

Accionistas

Tipos de accionistas

Accionistas

Proporción

BlackRock Institutional Trust Company, N.A.

10.76%

Meridian Venture Partners

4.46%

Vanguard Capital Management, LLC

3.62%

State Street Investment Management (US)

3.20%

Millennium Management LLC

2.37%

Otro

75.58%

Accionistas

Proporción

BlackRock Institutional Trust Company, N.A.

10.76%

Meridian Venture Partners

4.46%

Vanguard Capital Management, LLC

3.62%

State Street Investment Management (US)

3.20%

Millennium Management LLC

2.37%

Otro

75.58%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

42.89%

Investment Advisor/Hedge Fund

23.64%

Hedge Fund

20.43%

Research Firm

6.41%

Individual Investor

5.68%

Private Equity

4.46%

Pension Fund

2.51%

Corporation

1.92%

Bank and Trust

1.50%

Participación institucional



Actualizado: mié., 1 de abr

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2026Q1

555

23.15M

101.74%

+57.73K

2025Q4

507

21.97M

100.49%

+14.84K

2025Q3

525

21.96M

103.27%

+407.79K

2025Q2

506

21.46M

110.44%

-446.10K

2025Q1

489

21.61M

106.49%

-1.37M

2024Q4

469

21.12M

108.93%

+156.97K

2024Q3

453

20.75M

88.54%

+3.60M

2024Q2

425

17.36M

85.19%

+1.07M

2024Q1

403

16.22M

82.13%

-1.01M

2023Q4

390

16.10M

82.95%

+39.70K

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

BlackRock Institutional Trust Company, N.A.

2.45M

10.91%

+103.61K

+4.42%

Dec 31, 2025

Meridian Venture Partners

1.01M

4.53%

-150.00K

-12.88%

Aug 21, 2025

State Street Investment Management (US)

727.20K

3.24%

+15.50K

+2.18%

Dec 31, 2025

Millennium Management LLC

539.66K

2.41%

+474.42K

+727.14%

Dec 31, 2025

Dimensional Fund Advisors, L.P.

487.67K

2.18%

-17.76K

-3.51%

Dec 31, 2025

Soleus Capital Management, L.P.

486.24K

2.17%

+146.00K

+42.91%

Dec 31, 2025

Tang Capital Management, LLC

481.44K

2.15%

+163.94K

+51.63%

Dec 31, 2025

Deep Track Capital LP

477.68K

2.13%

+27.68K

+6.15%

Dec 31, 2025

ETFs relacionados



Actualizado: sáb., 6 de dic

Nombre

Proporción

Invesco Pharmaceuticals ETF

2.63%

State Street SPDR S&P Pharmaceuticals ETF

2.42%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.95%

Pacer US Small Cap Cash Cows Growth Leaders ETF

1.63%

Innovator IBD Breakout Opportunities ETF

1.38%

Innovator IBD 50 Fund ETF

1.02%

Invesco Dorsey Wright Healthcare Momentum ETF

0.98%

Invesco S&P SmallCap Health Care ETF

0.96%

Janus Henderson Small/Mid Cap Growth Alpha ETF

0.92%

First Trust Small Cap Growth AlphaDEX Fund

0.67%

Invesco Pharmaceuticals ETF

Proporción2.63%

State Street SPDR S&P Pharmaceuticals ETF

Proporción2.42%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

Proporción1.95%

Pacer US Small Cap Cash Cows Growth Leaders ETF

Proporción1.63%

Innovator IBD Breakout Opportunities ETF

Proporción1.38%

Innovator IBD 50 Fund ETF

Proporción1.02%

Invesco Dorsey Wright Healthcare Momentum ETF

Proporción0.98%

Invesco S&P SmallCap Health Care ETF

Proporción0.96%

Janus Henderson Small/Mid Cap Growth Alpha ETF

Proporción0.92%

First Trust Small Cap Growth AlphaDEX Fund

Proporción0.67%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones



Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos

Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos